Showing results (11-20 of 17) with videos related to
Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 17 results.
Cancers|April 30, 2021
Succinate Pathway in Head and Neck Squamous Cell Carcinoma: Potential as a Diagnostic and Prognostic MarkerXimena Terra, Victoria Ceperuelo-Mallafré, Carla Merma, et al.Cancer Immunology, Immunotherapy : CII|January 10, 2023
Determinants of activity and efficacy of anti-PD1/PD-L1 therapy in patients with advanced solid tumors recruited in a clinical trials unit: a longitudinal prospective biomarker-based studyJavier García-Corbacho, Alberto Indacochea, Azucena E González Navarro, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 25, 2022
Pembrolizumab Alone or With Chemotherapy for Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma in KEYNOTE-048: Subgroup Analysis by Programmed Death Ligand-1 Combined Positive ScoreBarbara Burtness, Danny Rischin, Richard Greil, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 11, 2022
Pembrolizumab With or Without Chemotherapy in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Updated Results of the Phase III KEYNOTE-048 StudyKevin J Harrington, Barbara Burtness, Richard Greil, et al.Cancer Immunology, Immunotherapy : CII|February 1, 2025
Blood-based prognostic scores and early dynamics under immunotherapy to select patients with metastatic solid tumors for continuing immune check-point inhibition: a prospective longitudinal studyJavier García-Corbacho, Alberto Indacochea, Iván Victoria, et al.Lancet (London, England)|November 5, 2019
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 studyBarbara Burtness, Kevin J Harrington, Richard Greil, et al.European Journal of Cancer (Oxford, England : 1990)|May 10, 2026
Randomized non-comparative phase II trial of nivolumab plus paclitaxel in subjects with recurrent/metastatic head and neck squamous cell carcinoma unable for cisplatin-based chemotherapy. NIVOTAX TTCC studyLara Iglesias Docampo, Neus Basté, Marc Oliva, et al.Pageof 2